2016
DOI: 10.14283/jpad.2016.97
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: The EU/US/CTAD Task Force, an international collaboration of AD investigators from industry and academia, met in Barcelona, Spain, on November 4th, 2015, to explore existing and planned patient registries and other clinical trial infrastructure meant to expedite recruitment of large numbers of participants into clinical trials and improve their productivity. The Task Force identified a number of approaches currently being tested around the world, including the use of predictive algorithms to identify individua… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
20
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 35 publications
(20 citation statements)
references
References 14 publications
0
20
0
Order By: Relevance
“… 7 The shift from intervention to prevention studies, which rely on the timely assessment of genetic, neuroimaging, and biofluid biomarkers, further exacerbate these challenges. 8 , 9 Consequently, it is common for AD/ADRD trials to experience high site staff turnover and low-enrolling sites, potentially leading to data quality issues.…”
Section: Introductionmentioning
confidence: 99%
“… 7 The shift from intervention to prevention studies, which rely on the timely assessment of genetic, neuroimaging, and biofluid biomarkers, further exacerbate these challenges. 8 , 9 Consequently, it is common for AD/ADRD trials to experience high site staff turnover and low-enrolling sites, potentially leading to data quality issues.…”
Section: Introductionmentioning
confidence: 99%
“…A promising approach to alleviation of the bottleneck is the establishment of trial-ready cohorts of candidates for early intervention trials 11 . A trial-ready cohort is a group of individuals who meet general eligibility requirements for clinical trials in the target population.…”
Section: Introductionmentioning
confidence: 99%
“…Cross-cohort analyses and networks of registries in AD have previously been established, each with its own objectives, e.g., to facilitate clinical trial recruitment [ 5 ], monitor changes in the incidence of dementia [ 6, 7 ], identify risk factors, improve early diagnosis, or address specific research questions [ 8–10 ]. In addition, publicly available collaborative resources such as the Global Alzheimer’s Association Interactive Network (GAAIN) research platform [ 11 ] have been set up to allow researchers to access data being collected across the globe and to promote consistency and comparability across cohort analyses.…”
Section: Introductionmentioning
confidence: 99%